Huadong Medicine: Independent financial advisor report on the adjustment of repurchase price and repurchase cancellation of some restricted stocks in the 2022 restricted stock incentive plan of huadong medicine limited by GuoSheng Securities Co., Ltd.

SZSI · Jun 15

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

华东医药：国盛证券有限责任公司关于华东医药股份有限公司2022年限制性股票激励计划调整回购价格及回购注销部分限制性股票之独立财务顾问报告

Huadong Medicine: Independent financial advisor report on the adjustment of repurchase price and repurchase cancellation of some restricted stocks in the 2022 restricted stock incentive plan of huadong medicine limited by GuoSheng Securities Co., Ltd.

Risk Disclaimer

Statement